Major French study confirms non-inferiority of Avastin versus Lucentis
A multicentre French study comparing bevacizumab (Avastin, Genentech) and ranibizumab (Lucentis, Genentech) found that both drugs were comparable in terms of clinical efficacy for the treatment of neovascular age-related macular degeneration (AMD).
Presenting the results of the Group d’Evaluation Français Avastin versus Lucentis (GEFAL) study at the 13th EURETINA Congress, Laurent Kodjikian MD of the University Hospital of Lyon, said that the outcomes are in line with those of the Comparison of AMD Treatment Trial (CATT) published in 2012.
The GEFAL study was a prospective, double-masked, randomised study conducted in 38 public and private-sector French ophthalmology centres from June 2009 to November 2011.
Latest Articles
Making Female Leadership More than a Moment
A remarkable global confluence of women in key positions.
ESCRS Talks Technology at AAO
Europe adopts technological advances, US still waiting for lenses and lasers.
Sorting Out Simultaneous Vision IOLs
The ESCRS Eye Journal Club discuss a new landmark paper on IOL classification and the need for harmonisation of terminology for presbyopic IOLs.
Big Advantages to Small-Aperture IOLs
Small-aperture IOLs offer superior image quality with increased range of focus.
Prioritising Self-Care
Benefits of maintaining physical, emotional, and mental health extend beyond the personal sphere.
Valuing Clinical Trial Design
How inclusivity and diversity can enhance scientific accuracy in research.
Knowing Iris Repair: Using Iridodiathermy in Iris Surgery
Prepare for decentred pupils and uneven irides in multiple situations.
Neuroprotectant Treatment for MacTel Type 2
Intravitreal implant releasing ciliary neurotrophic factor found safe and effective in pivotal trials.